Company intelligence / Profile preview

Quantum Molecular Pharmaceuticals

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Quantum Molecular Pharmaceuticals was a Canadian radiopharmaceutical company that specialized in the development of molecular imaging technologies and radiopharmaceuticals. The company is primarily recognized for its strategic joint venture with Positron Corporation, which led to the acquisition of IS2 Medical Systems and the expansion of cardiac PET imaging solutions. Based in Toronto, Quantum Molecular Pharmaceuticals also funded academic research into innovative medical devices, including PET-enabled surgical gloves. The company was active during the mid-2000s and was officially dissolved in 2013.

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: RadiopharmaceuticalSmall molecule
Industry: Biotech

Partnerships

Positron Corporation

Beyond the preview

Go deeper on Quantum Molecular Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quantum Molecular Pharmaceuticals.

Explore the full profile